Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

NCT07163273 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: NALIRIFOX
DRUG: Gemcitabine plus nab-Paclitaxel (GnP)

Sponsor

Northwell Health